| Primary |
| Epilepsy |
38.2% |
| Drug Use For Unknown Indication |
13.7% |
| Product Used For Unknown Indication |
10.1% |
| Convulsion |
6.1% |
| Hypertension |
4.3% |
| Gastric Ulcer |
3.6% |
| Constipation |
3.2% |
| Depression |
2.8% |
| Cerebral Infarction |
2.2% |
| Insomnia |
2.0% |
| Parkinson's Disease |
2.0% |
| Convulsion Prophylaxis |
1.9% |
| Gastritis |
1.7% |
| Diabetes Mellitus |
1.5% |
| Drug Eruption |
1.5% |
| Drug Exposure During Pregnancy |
1.1% |
| Infection Prophylaxis |
1.1% |
| Trigeminal Neuralgia |
1.1% |
| Atrial Fibrillation |
0.9% |
| Brain Neoplasm |
0.9% |
|
| Drug Rash With Eosinophilia And Systemic Symptoms |
18.2% |
| Stevens-johnson Syndrome |
14.0% |
| Toxic Epidermal Necrolysis |
10.2% |
| White Blood Cell Count Decreased |
6.7% |
| Oculomucocutaneous Syndrome |
5.6% |
| Drug Eruption |
4.9% |
| Rash |
4.9% |
| Interstitial Lung Disease |
4.6% |
| Agranulocytosis |
4.2% |
| Rhabdomyolysis |
3.9% |
| Calculus Urinary |
3.5% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
3.5% |
| Liver Disorder |
3.5% |
| Nephrolithiasis |
2.1% |
| Neuroleptic Malignant Syndrome |
2.1% |
| Pyrexia |
2.1% |
| Platelet Count Decreased |
1.8% |
| Anaemia |
1.4% |
| Drug Exposure During Pregnancy |
1.4% |
| Erythema Multiforme |
1.4% |
|
| Secondary |
| Epilepsy |
40.5% |
| Convulsion |
6.6% |
| Product Used For Unknown Indication |
6.5% |
| Parkinson's Disease |
6.2% |
| Drug Use For Unknown Indication |
4.2% |
| Hypertension |
4.1% |
| Gastric Ulcer |
3.4% |
| Prophylaxis |
3.4% |
| Pneumonia |
3.1% |
| Temporal Lobe Epilepsy |
2.7% |
| Constipation |
2.3% |
| Pyrexia |
2.3% |
| Gastritis |
2.2% |
| Insomnia |
2.2% |
| Foetal Exposure During Pregnancy |
1.9% |
| Depression |
1.8% |
| Pharyngitis |
1.8% |
| Status Epilepticus |
1.8% |
| Autism |
1.6% |
| Lennox-gastaut Syndrome |
1.6% |
|
| Stevens-johnson Syndrome |
8.8% |
| Suicidal Ideation |
8.0% |
| Nephrolithiasis |
7.3% |
| Sepsis |
7.3% |
| White Blood Cell Count Decreased |
6.6% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
5.8% |
| Calculus Urinary |
5.1% |
| Liver Disorder |
5.1% |
| Toxic Epidermal Necrolysis |
5.1% |
| Drug Eruption |
4.4% |
| Status Epilepticus |
4.4% |
| Toxic Skin Eruption |
4.4% |
| Uveitis |
4.4% |
| White Blood Cell Count Increased |
4.4% |
| Interstitial Lung Disease |
3.6% |
| Neuroleptic Malignant Syndrome |
3.6% |
| Gastroenteritis Eosinophilic |
2.9% |
| Platelet Count Decreased |
2.9% |
| Pyrexia |
2.9% |
| Rash Generalised |
2.9% |
|
| Concomitant |
| Epilepsy |
35.0% |
| Drug Use For Unknown Indication |
9.4% |
| Prophylaxis |
8.8% |
| Parkinson's Disease |
8.1% |
| Glioblastoma Multiforme |
4.4% |
| Complex Partial Seizures |
4.1% |
| Convulsion |
3.5% |
| Hypertension |
3.4% |
| Product Used For Unknown Indication |
2.7% |
| Constipation |
2.7% |
| Infection Prophylaxis |
2.6% |
| Convulsion Prophylaxis |
2.2% |
| Anaplastic Astrocytoma |
1.9% |
| Pneumonia |
1.9% |
| Lennox-gastaut Syndrome |
1.8% |
| Insomnia |
1.7% |
| Metastatic Renal Cell Carcinoma |
1.7% |
| Hiv Infection |
1.5% |
| Status Epilepticus |
1.4% |
| Gastric Ulcer |
1.3% |
|
| White Blood Cell Count Decreased |
17.6% |
| Rash |
7.5% |
| Status Epilepticus |
7.5% |
| White Blood Cell Count Increased |
7.0% |
| Pneumonia |
6.6% |
| Somnolence |
5.3% |
| Vomiting |
5.3% |
| Epilepsy |
4.8% |
| Pyrexia |
4.8% |
| Interstitial Lung Disease |
4.0% |
| Hepatic Function Abnormal |
3.5% |
| Staphylococcal Infection |
3.5% |
| Dystonia |
3.1% |
| Pulmonary Embolism |
3.1% |
| Urinary Tract Infection |
3.1% |
| Convulsion |
2.6% |
| Nasopharyngitis |
2.6% |
| Pneumonia Aspiration |
2.6% |
| Renal Impairment |
2.6% |
| Respiratory Failure |
2.6% |
|
| Interacting |
| Drug Effect Decreased |
59.4% |
| Epilepsy |
21.9% |
| Constipation |
9.4% |
| Gastritis |
9.4% |
|
| Surgery |
28.6% |
| White Blood Cell Count Decreased |
28.6% |
| Epilepsy |
14.3% |
| Status Epilepticus |
14.3% |
| Vision Blurred |
14.3% |
|
